Abstract

Clavaspirin peptide (CSP) is derived from the pharyngeal tissues of the tunicate Styela clava. The 23-amino acid peptide is histidine-rich and amidated at the N-terminus. CSP possesses low antimicrobial and high hemolytic activity at pH 7.4. Therefore, we designed 4 CSP analogs with substituted hydrophobic amino acids to reduce hydrophobic amino acid interactions. These modifications reduced the aggregation and cytotoxicity of the analogs at pH 7.4. The analogs also showed potent antimicrobial activity by accumulating on bacterial cell surfaces and inducing the lytic mechanism against gram-negative and gram-positive cells at pH 5.5 and 7.4. Moreover, exposure to the CSP-4 analog for up to 29 passages did not induce drug resistance in Staphylococcus aureus. Application of CSP-4 to inflamed skin of hairless mice infected with drug-resistant S. aureus (DRSA) significantly reduced skin infections without damaging dermal collagen or elastin. Topically applied CSP-4 penetrated 25–40 µm in the dermis within 30 min, reducing the levels of Toll-like receptor-2, nuclear factor kappa B (NF-κB), and the pro-inflammatory cytokines tumor necrosis factor- α (TNF-α) and interleukin-1β (IL-1 β). These results suggest that CSP-4 could be a promising topical antimicrobial agent for skin diseases caused by DRSA such as S. aureus CCARM 0027.

Highlights

  • The common use of antibiotics against bacteria has led to the emergence of many antibiotic-resistant pathogen strains

  • Previous studies demonstrated that Clavaspirin peptide (CSP) has weak antimicrobial activity and high hemolytic activity towards mammalian red blood cells (RBCs) at physiological pH [10]

  • Given that CSP-4 is less hydrophobic than other CSP analogues, we suggest that the increased antimicrobial activity www.oncotarget.com and reduced cytotoxicity were achieved by replacing hydrophobic residues with more hydrophilic residues (Supplementary Table 1)

Read more

Summary

Introduction

The common use of antibiotics against bacteria has led to the emergence of many antibiotic-resistant pathogen strains. Infections caused by multidrug resistant bacteria have become a significant problem. It is estimated that in Europe alone there are 171,200 healthcare-associated infections with multidrug-resistant Staphylococcus aureus (MRSA) each year, affecting both adults and children [1, 2]. There is an urgent need to develop new antibiotic agents. One potentially effective strategy is to develop new agents derived from antimicrobial peptides (AMPs) [3], which are produced natively as part of the host defense response to microbial infections.

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call